Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma
NCT00240565
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
93
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG:
Tositumomab 450 mg
DRUG:
Tositumomab 35 mg
Sponsor
GlaxoSmithKline